You are here

Lynparza

AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns

Fierce Pharma

Sun, 09/25/22 - 02:28 pm

Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility

Seeking Alpha

Tue, 07/19/22 - 10:18 am

clinical trials

colorectal cancer

ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options

Fierce Biotech

Fri, 05/27/22 - 10:17 am

FDA clears AstraZeneca, Merck drug to treat some genetic breast cancers early

BioPharma Dive

Mon, 03/14/22 - 10:26 am

genetic breast cancer

ASCO-GU – prostate cancer PARPS move to the front line

EP Vantage

Sun, 02/20/22 - 11:44 am

prostate cancer

PARP inhibitors

Clovis Oncology

AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises

Endpoints

Tue, 02/15/22 - 11:31 pm

prostate cancer

Go or no go? Roche’s fresh start for a new year

EP Vantage

Mon, 12/20/21 - 10:59 am

FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy

Pharmaceutical Business Review

Wed, 12/1/21 - 10:21 am

BRCA-mutant breast cancer

PROpel study backs Lynparza combo in first-line prostate cancer

Pharmaforum

Fri, 09/24/21 - 11:06 am

clinical trials

prostate cancer

AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report

Fierce Pharma

Mon, 06/7/21 - 08:45 pm

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

BioSpace

Mon, 06/7/21 - 08:41 pm

An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?

BioPharma Dive

Thu, 06/3/21 - 11:11 pm

genetic breast cancer

AZ aims at Pfizer, GSK with potential new PARP cancer drug

Pharmaforum

Wed, 04/14/21 - 09:28 am

PARP inhibitors

AZ showcases data for next-generation PARP inhibitor AZD5305

PM Live

Mon, 04/12/21 - 10:39 am

Moving up the lines, AstraZeneca stakes another PhIII win for Lynparza as adjuvant breast cancer therapy

Endpoints

Wed, 02/17/21 - 11:21 am

clinical trials

BRCA-mutant breast cancer

Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan

Motley Fool

Tue, 12/29/20 - 10:57 am

prostate cancer

pancreatic cancer

KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor

Fierce Biotech

Sun, 10/25/20 - 11:28 pm

KSQ Therapeutics

PARP inhibitors

ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

BioSpace

Sun, 09/20/20 - 08:00 pm

clinical tirals

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

Motley Fool

Wed, 05/20/20 - 11:23 pm

prostate cancer

AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval

Endpoints

Mon, 05/11/20 - 10:40 am

Pages